How Breast Cancer Is Classified: The Three Systems Doctors Use

Doctors classify breast cancer using three complementary systems: the type of cancer and where it started, how far it has spread, and what the cancer cells respond to. Together, these three descriptions form a complete picture of the cancer and shape the care team’s planning. If your own report feels like a wall of unfamiliar terms, your care team can walk you through what each part means for your situation.

Key Takeaways

Breast cancer is described in three ways: the cancer type (where it started and whether it is invasive), the stage (how far it has spread), and the receptor status (whether the cells respond to hormones or the HER2 protein).
“In situ” means the abnormal cells are still contained where they started; “invasive” means they have grown into nearby breast tissue.
Stage is built from three letters — T, N, and M — that describe the tumor, nearby lymph nodes, and any distant spread; the letters combine into stages numbered 0 through IV.
Receptor tests (ER, PR, and HER2) describe what the cancer cells respond to, which helps the care team choose the right kind of treatment approach.
The same cancer can have several labels at once — for example, an invasive ductal, grade 2, stage II, hormone-receptor-positive cancer — because each label comes from a different system.
These labels describe the cancer’s features, not your future; individual cases differ, so talk through your own report with your care team.

The First System: Where the Cancer Started and How It Looks

The first classification system describes the cancer itself: what kind of breast tissue it grew from, whether it has stayed put or started to spread, and how abnormal the cells look under the microscope. This information comes mainly from the biopsy — the sample of tissue removed and examined by a pathologist. Because it is based on what the cells look like, this system is sometimes called the histologic classification, from the Greek word for tissue.

In situ or invasive

One of the first things a report tells you is whether the cancer is in situ or invasive. “In situ” is Latin for “in its original place” — the abnormal cells are still contained inside the milk duct or lobule where they started, and have not grown into the surrounding breast tissue. Ductal carcinoma in situ (DCIS) is the most widely discussed example.

“Invasive” (sometimes written as “infiltrating”) means the cancer cells have grown beyond the walls of the duct or lobule and into nearby breast tissue. This does not mean the cancer has spread to the rest of the body — it means it has moved past its starting point locally. Most breast cancers that people are diagnosed with are invasive, and the distinction between in situ and invasive is one of the most important lines in any classification, because it changes what the care team recommends.

Ductal or lobular

Breast cancer is also named for where it began. Cancers that start in the milk ducts are called ductal; cancers that start in the lobules, the small glands that make milk, are called lobular. Invasive ductal carcinoma is the form of breast cancer people encounter most often in reports and conversations, while invasive lobular carcinoma is the next most recognized type.

Beyond these two, there is a long list of less common types — tubular, mucinous, papillary, medullary, metaplastic, and others — each named for the pattern the cells form under the microscope. Some cancers are mixed, meaning the pathologist sees more than one pattern in the same tumor. Knowing the type matters because different types can behave differently, though the ductal-versus-lobular distinction is the one that appears in nearly every report.

Grade: how the cells look

The grade describes how abnormal the cancer cells look compared with healthy breast cells. Pathologists assign one of three grades: grade 1 cells look fairly close to normal and tend to grow more slowly; grade 3 cells look very abnormal and tend to grow more quickly; grade 2 falls in between. Grade is determined by features such as how the cells are arranged, how different their nuclei look, and how many of them are dividing.

Grade is easy to confuse with stage, but they answer different questions. Grade asks, “What do these cells look like?” while stage asks, “How far have they gone?” A small, low-grade cancer and a large, high-grade cancer can be at the same stage, and two cancers at the same stage can have different grades.

A doctor pointing to a wall chart while talking with a woman patient in a bright clinic room

The Second System: How Far It Has Spread

The second system is stage, and it answers a different question from everything above: not what the cancer looks like, but how far it has traveled. Stage is built from three measurements that doctors call TNM — T for the size of the tumor, N for whether nearby lymph nodes are involved, and M for whether the cancer has spread to distant parts of the body. The three pieces combine into an overall stage numbered from 0 to IV: stage 0 describes noninvasive (in situ) cancer, stages I through III describe invasive cancers still considered local or regional, and stage IV describes cancer that has spread to distant parts of the body.

Stage is often the number people remember, because it gives a single, compact summary of how far the disease has gone. It also plays a central role in planning: the general approach to a stage I cancer differs from the approach to a stage III cancer. But stage alone never tells the whole story, which is why the other two systems exist. Two cancers at the same stage can be very different diseases if their types and receptor statuses differ.

The Third System: What the Cancer Cells Respond To

The third system is about the cancer cells’ receptors — proteins on or in the cells that respond to signals from the body. Lab tests on the biopsy sample check for three of them: the estrogen receptor (ER), the progesterone receptor (PR), and a protein called HER2. The results are reported as positive or negative, and they matter enormously, because they point the care team toward the kinds of treatment that are most likely to work against that particular cancer.

ER and PR: hormone receptors

Some breast cancer cells carry receptors for the hormones estrogen and progesterone. When a report says a cancer is estrogen-receptor-positive (ER-positive) or progesterone-receptor-positive (PR-positive), it means those hormones can attach to the cancer cells and encourage them to grow. Cancers that are ER-positive, PR-positive, or both are often described together as hormone-receptor-positive. When neither receptor is found, the cancer is called hormone-receptor-negative.

Hormone receptor status is one of the most useful pieces of information in the whole classification, because cancers that feed on hormones can often be treated with therapies that block those hormones. It also explains why two people at the same stage can receive different plans.

HER2: a growth-promoting protein

HER2 is a protein found on the surface of breast cells that helps control how they grow. In some breast cancers, the cells make far more HER2 than normal — these are called HER2-positive cancers. In others, HER2 levels are normal or low, and the cancer is called HER2-negative. Pathologists test for HER2 with special stains and, when needed, genetic tests that look at the HER2 gene itself.

HER2 status matters for the same reason hormone receptors do: it identifies a specific feature of the cancer that certain treatments are designed to target. You may also hear the term HER2-low, a newer category for cancers that have some HER2 but not enough to count as HER2-positive. Because definitions in this area continue to be refined, it is worth asking your own care team exactly how your HER2 result was determined and what it means for your plan.

Triple-negative: what it means when all three are negative

When a cancer tests negative for ER, negative for PR, and negative for HER2, it is called triple-negative breast cancer. The name simply describes what the lab tests did not find — it is not a statement about how serious the cancer is. Triple-negative cancers are treated differently from hormone-receptor-positive or HER2-positive cancers, because the targeted approaches designed for those receptors do not apply.

Hearing “triple-negative” can be frightening. The name simply describes what the lab tests did not find, and it is used so the care team can choose the right tools — just like every other label in these three systems. If this is your result, ask your team which features of your particular cancer they are focusing on.

A woman reviewing neatly organized medical papers at a home table in soft daylight

Why All Three Systems Matter Together

None of these three systems stands alone. A complete description of a breast cancer draws one label from each: the type and grade, the stage, and the receptor status. That is why a report might describe a cancer as “invasive ductal carcinoma, grade 2, stage IIA, ER-positive, PR-positive, HER2-negative.” Each piece answers a different question, and the care team needs all the answers before it can plan.

This is also why two people with “stage II breast cancer” can receive different plans: one cancer may be hormone-receptor-positive and the other triple-negative, or one grade 1 and the other grade 3. Stage gives the broad outline; type and receptor status fill in the details.

System	Question it answers	Examples of labels
Type and grade	Where did it start, and what do the cells look like?	In situ or invasive; ductal or lobular; grade 1, 2, or 3
Stage (TNM)	How far has it spread?	T, N, and M measurements grouped into stages 0 through IV
Receptor status	What do the cells respond to?	ER-positive or negative; PR-positive or negative; HER2-positive, HER2-low, or negative; triple-negative

If you want to see how these labels combine in real cancer types, the site’s complete guide to how breast cancer is classified and how the types differ walks through the major types side by side. And because the same systems are used to describe cancers everywhere, the American Cancer Society (cancer.org) and the National Cancer Institute (cancer.gov) publish current, detailed explanations of each one — useful reading if you want to go deeper than any single article can go. Current figures and detailed definitions change over time, so those official sources are the right place to check the latest information.

Questions to Ask Your Doctor

Classification terms are worth discussing directly with the team that knows your case. These questions can help you turn your pathology report into a conversation:

What type of breast cancer do I have, and is it in situ or invasive?
What is my grade, and what did the pathologist see that led to that grade?
What is my TNM breakdown — what are my T, N, and M values?
What is my overall stage, and how was it determined?
What are my ER, PR, and HER2 results, and were any tests repeated to confirm them?
Which of these features is most influencing my treatment plan?
Could any of these classifications change if more testing is done?

Bring the actual report to the appointment if you can — pointing at the exact line that confuses you gets you a clearer answer than describing it from memory. A trusted person taking notes is a help, too.

Frequently Asked Questions

Why does my report use words like “ductal” and “invasive” together?

Because they come from different parts of the classification. “Ductal” says where the cancer started (the milk ducts); “invasive” says it has grown beyond its starting point. A full label stacks one term from each system, so combinations like “invasive ductal carcinoma” are completely normal.

Is stage the same as grade?

No. Stage describes how far the cancer has spread (the TNM system, grouped into stages 0 through IV). Grade describes how abnormal the cells look under the microscope (grades 1 to 3). They are independent: a cancer can be low-grade but higher-stage, or high-grade but lower-stage.

Can my classification change over time?

The type and grade rarely change, but stage can be updated if new information appears — for example, if surgery reveals more lymph node involvement than imaging showed, the stage may be adjusted. Receptor tests are sometimes repeated, and results can occasionally differ between the biopsy and the surgical sample. Your team will tell you if any update changes your plan.

What if my report mentions terms my doctor never explained?

That is common — reports are written for pathologists and oncologists, not for patients. Make a list of the unfamiliar terms and bring it to your next appointment, or call the office and ask for help reading the report. Understanding your classification helps you follow every conversation that comes after.

This article is for general educational purposes only and is not medical, legal, or financial advice. It does not replace professional care. Talk to your doctor or care team about your own situation. If you think you may have a medical emergency, call 911.